Dr Carl Firth is the Founder and CEO of ASLAN pharmaceuticals, a Singapore company with offices in Taiwan and China, which is developing novel medicines for global markets in oncology and inflammation. Previously, Carl was the Head of Asia Healthcare at Bank of America Merril Lynch, supporting public and private financing of healthcare companies across the region and advising on M&A transactions.
Prior to joining the banking industry, he worked for AstraZeneca for 10 years in various commercial and R&D roles, including Regional Business Development, Director APAC and Director of New Product Development in China.
Recently, Calr was chosen as one of Scrip's top 10 pharmaceutical leaders alongside notable industry veterans such as Ken Frazier, CEO of MErck and Andrew Witty, CEO of GSK.
Carl holds a PhD from Cambridge University in Molecular Biology (Trinity College), an Executive MBA from London Business School and degree in Molecular Biology from Cambridge University. Carl is the Independent Director for Hong Kong listed Uni-Biosciences and Singapore's Exploit Technologies, as well as Adjunct Professor at Duke-NUS Medical School.